Jan. 21, 2011
/PRNewswire/ -- Celsion Corporation (Nasdaq: CLSN), a leading oncology drug development company dedicated to the development and commercialization of innovative oncology drugs, today announced that it has completed its registered direct offering of 5,000 shares of 8% redeemable convertible preferred stock with a stated value of
and warrants to purchase up to 2,083,333 shares of common stock. The convertible preferred stock and warrants were sold in units (the "Units"), with each Unit consisting of one share of convertible preferred stock and a warrant to purchase up to 416.6666 shares of common stock at an exercise price of
per whole share of common stock. The Units were sold to unaffiliated third party investors at a negotiated purchase price of
per Unit and to officers and directors at an at-the-market price of
per Unit in accordance with the NASDAQ Stock Market Rules. Each share of preferred stock is convertible into shares of common stock at an initial conversion price of
per share, subject to adjustment in the event of stock splits, recapitalizations or reorganizations that affect all holders of common stock equally. The Company expects to receive gross proceeds from the offering of approximately
, before deducting placement agents' fees and estimated offering expenses. The Company intends to use the net proceeds from the sale of the Units pursuant to this offering for general corporate purposes, including the funding of the clinical development of its product pipeline of cancer drugs.
Dominick & Dominick LLC acted as placement agent for the offering. Copies of the prospectus supplement and accompanying base prospectus relating to these securities can be obtained at the SEC's website at
or by writing or calling the Company at 10220-L Old Columbia Road,
, Chief Financial Officer, (410) 290-5390.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in this offering. There shall not be any sale of these securities in any state or jurisdiction in which such offering, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.